Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma
Completed · Phase 2
Conditions studied: Neuroblastoma
In brief
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining colony-stimulating factors, such as sargramostim, with monoclonal antibodies may be an effective treatment for advanced neuroblastoma. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody 3F8 plus sargramostim in treating patients who have advanced neuroblastoma.
Key facts
- Study ID
- NCT00002560
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 40
- Starts
- 1994-02-01
- Expected to finish
- 2005-04-01
- Last updated by the study team
- 2013-06-28
Who can join
Age: 2 and older, up to 21. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.